BriaCell (BCTX) Therapeutics announces that it has been granted New Zealand Patent No. 785587 titled “WHOLE-CELL CANCER VACCINES AND METHODS FOR SELECTION THEREOF”. The patent covers methods of selecting its whole-cell cancer immunotherapy technology for subjects with cancer based on HLA allele profile matching, providing exclusivity through February 27, 2037, and supporting BriaCell’s precision medicine approach aimed at personalizing immunotherapy for improved patient outcomes. “We are thrilled that the New Zealand Patent Office recognized the innovative nature of BriaCell’s novel whole cell immunotherapy and its potential therapeutic applications for cancer patients,” said Dr. William V. Williams, President and CEO of BriaCell.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCTX:
- BriaCell’s BriaPro Files Patent for Innovative Cancer Treatment Platform
- BriaCell subsidiary BriaPro files patent application for TILsRx
- BriaCell to Present Key Clinical Data at ESMO 2025
- Three new option listings and ten option delistings on July 21st
- BriaCell Therapeutics Secures $15 Million in Public Offering